MARC Record from marc_columbia

LEADER: 06135cam a2200841Ia 4500
001 11035599
005 20220326224415.0
006 m o d
007 cr |n|||||||||
008 111105s2012 enka ob 001 0 eng d
035 $a(OCoLC)ocn798795445
035 $a(NNC)11035599
040 $aCOO$beng$epn$cCOO$dKNOVL$dOCLCQ$dDEBSZ$dCOD$dTJC$dUKRSC$dOHS$dOCLCO$dITD$dYDXCP$dN$T$dMYG$dKNOVL$dOCLCF$dNLGGC$dNJR$dZCU$dKNOVL$dOCLCA$dOCLCQ$dAGLDB$dBUF$dOCLCQ$dVTS$dRRP$dREC$dSTF$dOCLCQ$dOCLCO$dOCLCA$dAJS$dHS0$dOCLCA$dOCLCO
019 $a761929532
020 $a9781621981404$q(electronic bk.)
020 $a1621981401$q(electronic bk.)
020 $a9781849733410$q(electronic bk.)
020 $a1849733414$q(electronic bk.)
020 $a9781849731676
020 $a1849731675
020 $z9781849731669
020 $z1849731667
024 7 $a10.1039/9781849733410$2doi
035 $a(OCoLC)798795445$z(OCoLC)761929532
037 $b00154291
050 4 $aRS420
060 4 $aQV 744
072 7 $aMED$x023000$2bisacsh
072 7 $aMED$x058170$2bisacsh
072 7 $aMED$x071000$2bisacsh
072 7 $aMED$x072000$2bisacsh
082 04 $a615.19$223
049 $aZCUA
245 00 $aDrug design strategies :$bquantitative approaches /$cedited by David J. Livingstone, Andrew M. Davis.
260 $aCambridge :$bRoyal Society of Chemistry ;$a[LaVergne] :$b[Ingram Publisher Services],$c©2012.
300 $a1 online resource (516 pages) :$billustrations
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
490 1 $aRSC Drug Discovery Series ;$vno. 13
504 $aIncludes bibliographical references and index.
520 3 $aThis book brings together drug design practitioners, all leaders in their field, who are actively advancing the field of quantitative methods to guide drug discovery, from structure-based design to empirical statistical models - from rule-based approaches to toxicology to the fields of bioinformatics and systems biology. The aim of the book is to show how various facets of the drug discovery process can be addressed in a quantitative fashion (ie: numerical analysis to enable robust predictions to be made). Each chapter includes a brief review of the topic showing the historical development of quantitative approaches, a survey/summary of the current state-of-the-art, a selection of well chosen examples with some worked through and an appreciation of what problems remain to be overcome as well as an indication of how the field may develop. After an overview of quantitative approaches to drug design the book describes the development of concepts of "drug-like properties", of quantitative structure-activity relationships and molecular modelling, and in particular, structure-based design approaches to guide lead optimisation. How to manage and describe chemical structures, underpins all quantitative approaches to drug design and these are described in the following chapters. The next chapter covers the value of a quantitative approach, and also the challenge which is to describe the confidence in any prediction, and methods to assess predictive model quality. The later chapters describe the application of quantitative approaches to describing and optimising potency, selectivity, drug metabolism and pharmacokinetic properties and toxicology, and the design of chemical libraries to feed the screening approaches to lead generation that underpin modern drug discovery. Finally the book describes the impact of bioinformatics, current status of predicting ligand affinity direct from the protein structure, and the application of quantitative approaches to predicting environmental risk. The book provides a summary of the current state-of-the-art in quantitative approaches to drug design, and future opportunities, but it also provides inspiration to drug design practitioners to apply careful design, to make best use of the quantitative methods that are available, while continuing to improve them. Drug discovery still relies heavily on random screening and empirical screening cascades to identify leads and drugs and the process has many failures to deliver only a small handful of drugs. With the rapidly escalating costs of drug discovery and development together with spiralling delivery, quantitative approaches hold the promise of shifting the balance of success, to enable drug discovery to maintain its economic viability.
505 0 $aI-iv; v-vi; vii-xviii; 1-34; 35-59; 60-87; 88-107; 108-163; 164-191; 192-219; 267-278; 220-241; 242-266; 279-311; 312-344; 345-366; 367-396; 397-439; 440-457; 458-478; 479-498
650 0 $aDrugs$xDesign.
650 0 $aDecision making$xMathematical models.
650 0 $aChemical models.
650 0 $aQSAR (Biochemistry)
650 12 $aDrug Design
650 12 $aDrug Discovery
650 2 $aComputer Simulation
650 22 $aDecision Support Techniques
650 22 $aModels, Chemical
650 22 $aModels, Molecular
650 22 $aQuantitative Structure-Activity Relationship
650 6 $aMédicaments$xConception.
650 6 $aSimulation par ordinateur.
650 6 $aPrise de décision$xModèles mathématiques.
650 6 $aModèles chimiques.
650 6 $aRelations structure-activité quantitatives (Biochimie)
650 7 $asimulation.$2aat
650 7 $aMEDICAL$xDrug Guides.$2bisacsh
650 7 $aMEDICAL$xNursing$xPharmacology.$2bisacsh
650 7 $aMEDICAL$xPharmacology.$2bisacsh
650 7 $aMEDICAL$xPharmacy.$2bisacsh
650 7 $aDrugs$xDesign.$2fast$0(OCoLC)fst00898790
655 0 $aElectronic books.
655 4 $aElectronic books.
700 1 $aLivingstone, D.$q(David)
700 1 $aDavis, Andrew M.$c(Chemist)
776 08 $iPrint version:$tDrug design strategies.$dCambridge : Royal Society of Chemistry, 2012$z9781849731676$w(OCoLC)759585091
830 0 $aRSC drug discovery series ;$v13.
856 40 $uhttp://www.columbia.edu/cgi-bin/cul/resolve?clio11035599$zACADEMIC - Pharmaceuticals, Cosmetics & Toiletries
852 8 $blweb$hEBOOKS